Alpha Cognition Past Earnings Performance
Past criteria checks 0/6
Alpha Cognition's earnings have been declining at an average annual rate of -6.8%, while the Biotechs industry saw earnings growing at 34.1% annually. Revenues have been growing at an average rate of 93.7% per year.
Key information
-6.82%
Earnings growth rate
38.25%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 93.74% |
| Return on equity | -44.25% |
| Net Margin | -234.84% |
| Next Earnings Update | 13 Aug 2026 |
Recent past performance updates
Recent updates
Is Alpha Cognition (NASDAQ:ACOG) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ACOG: Phase 4 Tolerability Study Will Drive Future Alzheimer’s Launch Traction
The updated analyst price target for Alpha Cognition shifts from about $20 to roughly $14.67, as analysts factor in revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E, while still highlighting the market opportunity for Zunveyl in treating mild to moderate Alzheimer's dementia. Analyst Commentary Recent Street research on Alpha Cognition focuses on how Zunveyl, its prodrug of galantamine for mild to moderate Alzheimer’s dementia, might translate into commercial traction and support the revised valuation framework behind the updated price target.
ACOG: Early Dementia Therapy Launch Will Drive Bullish Repricing Potential
Analysts have adjusted their 12 month price target for Alpha Cognition to $12 from $14, citing early commercialization of Zunveyl for mild to moderate Alzheimer's dementia and what they view as a significant market opportunity, with high patient and prescriber willingness to try the therapy. Analyst Commentary Recent research coverage on Alpha Cognition has focused on the early commercialization of Zunveyl and the perceived market opportunity in mild to moderate Alzheimer's dementia.
Long Term Care Adoption And Real World Studies Will Transform This Cognitive Therapy Narrative
Catalysts About Alpha Cognition Alpha Cognition develops and commercializes therapies for cognitive disorders, with a primary focus on Alzheimer’s disease through its oral treatment ZUNVEYL. What are the underlying business or industry changes driving this perspective?Payer Friction And Slow Adoption Will Challenge Alzheimer’s Therapy Before Long Term Potential Emerges
Catalysts About Alpha Cognition Alpha Cognition is a biopharmaceutical company focused on commercializing ZUNVEYL for mild to moderate Alzheimer’s disease and advancing related formulations and indications. What are the underlying business or industry changes driving this perspective?We Think Alpha Cognition (NASDAQ:ACOG) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We're Interested To See How Alpha Cognition (NASDAQ:ACOG) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Revenue & Expenses Breakdown
How Alpha Cognition makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 11 | -25 | 34 | 3 |
| 31 Dec 25 | 10 | -21 | 29 | 2 |
| 30 Sep 25 | 7 | -19 | 20 | 2 |
| 30 Jun 25 | 5 | -20 | 15 | 3 |
| 31 Mar 25 | 3 | -12 | 10 | 3 |
| 31 Dec 24 | 0 | -15 | 8 | 4 |
| 30 Sep 24 | 0 | -15 | 8 | 4 |
| 30 Jun 24 | 0 | -16 | 8 | 4 |
| 31 Mar 24 | 0 | -17 | 8 | 5 |
| 31 Dec 23 | 0 | -14 | 5 | 5 |
| 30 Sep 23 | 0 | -12 | 5 | 6 |
| 30 Jun 23 | 0 | -11 | 4 | 6 |
| 31 Mar 23 | 0 | -11 | 4 | 8 |
| 31 Dec 22 | 0 | -12 | 5 | 9 |
| 30 Sep 22 | 0 | -11 | 5 | 9 |
| 30 Jun 22 | 0 | -13 | 4 | 10 |
| 31 Mar 22 | 0 | -10 | 4 | 8 |
| 31 Dec 21 | 0 | -20 | 3 | 8 |
| 30 Sep 21 | 0 | -18 | 2 | 7 |
| 30 Jun 21 | 0 | -15 | 2 | 5 |
| 31 Mar 21 | 0 | -17 | 1 | 5 |
| 31 Dec 20 | 0 | -6 | 1 | 5 |
| 30 Sep 20 | 0 | -6 | 1 | 5 |
Quality Earnings: ACOG is currently unprofitable.
Growing Profit Margin: ACOG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACOG is unprofitable, and losses have increased over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare ACOG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACOG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (67.9%).
Return on Equity
High ROE: ACOG has a negative Return on Equity (-44.25%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/11 20:37 |
| End of Day Share Price | 2026/08/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alpha Cognition Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Nazibur Rahman | Maxim Group |
| Ryan Deschner | Raymond James & Associates |